Specialty Pharma Journal Specialty, Precision & Technology
CAMBRIDGE, Mass. & SUMMIT, N.J.–(BUSINESS WIRE)–bluebird bio, Inc. (Nasdaq:BLUE) and Celgene Corporation (NASDAQ:CELG) announced initial data from the ongoing Phase 1 clinical study of bb21217 (CRB-402), an investigational next-generation anti-BCMA CAR T cell therapy being studied in patients with relapsed/refractory multiple myeloma. The data were presented by Nina Shah, M.D., …
Tag Archives: Bluebird Bio
December, 2018
August, 2018
-
23 August
bluebird bio and Gritstone Oncology Collaborate to Develop Novel Cancer Cell Therapies
CAMBRIDGE, Mass. & EMERYVILLE, Calif.–(BUSINESS WIRE)–bluebird bio, Inc. (Nasdaq: BLUE) and Gritstone Oncology, Inc. today announced a collaboration to research, develop and commercialize products for the treatment of cancer using cell therapy. Gritstone Oncology will leverage its proprietary EDGE™ artificial intelligence platform to analyze specific tumor types to identify tumor-specific targets and natural T-cell …
-
6 August
Regeneron and bluebird bio Collaborate for Development of New Cell Therapies for Cancer
TARRYTOWN, N.Y. and CAMBRIDGE, Mass., Aug. 6, 2018 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and bluebird bio, Inc. (NASDAQ: BLUE) today announced a collaboration to apply their respective technology platforms to the discovery, development and commercialization of novel immune cell therapies for cancer. The collaborators will specifically leverage Regeneron’s VelociSuite® platform technologies for the discovery and characterization of fully human …
May, 2018
-
24 May
FDA Grants Breakthrough Therapy Designation to Lenti-D for the Treatment of Cerebral Adrenoleukodystrophy
CAMBRIDGE, Mass.–(BUSINESS WIRE)–bluebird bio, Inc. (Nasdaq: BLUE) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Lenti-D™ for the treatment of patients with cerebral adrenoleukodystrophy (CALD), a rare, serious and life-threatening hereditary neurological disorder. Breakthrough Therapy designation is designed to expedite the development and …
-
14 May
Medigene Expands T-Cell Receptor Deal with Bluebird bio to up to $1.5 Billion
Medigene AG (MDG1, Frankfurt, Prime Standard), Germany, today announced the significant expansion of its successful strategic alliance with bluebird bio, a leader in gene and cell therapies, focusing on the research and development of T cell receptor-modified T cell (TCR-T) immunotherapies for the treatment of cancer. “We are delighted to …
December, 2017
-
11 December
Celgene and bluebird bio’s CAR T Cell Therapy Demonstrates Positive Results in Multiple Myeloma Trial
SUMMIT, N.J. & CAMBRIDGE, Mass.–(BUSINESS WIRE)– Celgene Corporation (NASDAQ: CELG) and bluebird bio, Inc. (Nasdaq: BLUE) today announced that updated results from the ongoing CRB-401 Phase 1 clinical study of bb2121, an investigational anti-B-cell maturation antigen (BCMA) CAR T cell therapy, in 21 patients with late-stage relapsed/refractory multiple myeloma will be presented in an oral presentation …
-
8 December
bluebird bio and TC BioPharm Collaborate to Develop Gamma Delta CAR T Cell Products for Cancer Immunotherapy
CAMBRIDGE, Mass. & EDINBURGH, Scotland–(BUSINESS WIRE)–bluebird bio, Inc. (Nasdaq: BLUE) and Scottish immunotherapy company TC BioPharm, Ltd. (TCB) today announced a strategic collaboration and license agreement focused on gamma delta CAR T cells. The companies will work together to advance TC BioPharm’s lead CAR-engineered gamma delta T cell program into clinical …
November, 2017
-
29 November
bluebird bio Acquires North Carolina Manufacturing Facility and Executes Multiple Global Supply Agreements
CAMBRIDGE, Mass.–(BUSINESS WIRE)–bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene and cell therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced it has acquired a 125,000-square foot manufacturing facility in Durham, North Carolina. Once construction and validation is complete, the site …
-
3 November
bluebird bio to Present New Data from Studies of its Therapies for Sickle Cell Disease and Multiple Myeloma
CAMBRIDGE, Mass.–(BUSINESS WIRE)–bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that four oral and seven poster presentations will feature data from bluebird programs during the 59th Annual Meeting of the American Society …
October, 2017
-
6 October
Bluebird Gene Therapy Halts Progression of Cerebral Adrenoleukodystrophy
CAMBRIDGE, Mass.–(BUSINESS WIRE)–bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for serious genetic diseases and T cell-based immunotherapies for cancer, today announced that interim data from an initial cohort of 17 patients in the ongoing Phase 2/3 Starbeam Study (ALD-102) evaluating Lenti-D™ investigational …